文献速递糖尿病

糖尿病肾病非蛋白尿表型与蛋白尿表型的倾向评分匹配全国活检队列分析

Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study.
PubMed 文献 · Diabetes Care · 2019-03-04

中位随访1.9年,非蛋白尿组5年CKD进展无生存率86.6%,蛋白尿组30.3%(P<0.001),全因死亡亦更低(P=0.005)。

要点

  • 非蛋白尿糖尿病肾病患者血压控制更好、典型病理病变更少。
  • 非蛋白尿组5年CKD进展无生存率86.6%,显著高于蛋白尿组30.3%。
  • 非蛋白尿组全因死亡率也显著低于蛋白尿组。

核心结论

  • 非蛋白尿型糖尿病肾病患者血压控制更佳、典型形态学改变更少,CKD进展和全因死亡风险更低。

研究设计与样本

  • 回顾性分析日本全国多中心肾活检登记中526例eGFR<60 mL/min/1.73 m²的2型糖尿病患者。

主要发现

  • 非蛋白尿组收缩压更低、病理病变严重程度更轻。
  • 中位随访1.9年(IQR 0.9-5.0年),5年CKD进展无生存率非蛋白尿组86.6%(95%CI 72.5-93.8),蛋白尿组30.3%(95%CI 22.4-38.6),log-rank P<0.001。
  • 肾脏风险降低在所有亚组分析中一致。
  • 非蛋白尿组全因死亡率更低(log-rank P=0.005)。

关键数值与推荐

  • 非蛋白尿定义:UACR<300 mg/g;蛋白尿定义:UACR≥300 mg/g。
  • 主要终点:CKD进展,定义为新发终末期肾病、eGFR下降≥50%或血清肌酐翻倍。
  • 次要终点:全因死亡率。

临床怎么用

  • 对eGFR<60 mL/min/1.73 m²的2型糖尿病患者,即使无蛋白尿也应重视肾活检病理评估和血压管理。
  • 非蛋白尿表型肾脏预后较好,但仍需监测CKD进展和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinicopathological characteristics, renal prognosis, and mortality in patients with type 2 diabetes and reduced renal function without overt proteinuria are scarce. RESEARCH DESIGN AND METHODS: We retrospectively assessed 526 patients with type 2 diabetes and reduced renal function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), who underwent clinical renal biopsy and had follow-up data, from Japan's nationwide multicenter renal biopsy registry. For comparative analyses, we derived one-to-two cohorts of those without proteinuria versus those with proteinuria using propensity score-matching methods addressing the imbalances of age, sex, diabetes duration, and baseline eGFR. The primary end point was progression of chronic kidney disease (CKD) defined as new-onset end-stage renal disease, decrease of eGFR by ≥50%, or doubling of serum creatinine. The secondary end point was all-cause mortality. RESULTS: Eighty-two patients with nonproteinuria (urine albumin-to-creatinine ratio [UACR] <300 mg/g) had lower systolic blood pressure and less severe pathological lesions compared with 164 propensity score-matched patients with proteinuria (UACR ≥300 mg/g). After a median follow-up of 1.9 years (interquartile range 0.9-5.0 years) from the date of renal biopsy, the 5-year CKD progression-free survival was 86.6% (95% CI 72.5-93.8) for the nonproteinuric group and 30.3% (95% CI 22.4-38.6) for the proteinuric group (log-rank test P < 0.001). The lower renal risk was consistent across all subgroup analyses. The all-cause mortality was also lower in the nonproteinuric group (log-rank test P = 0.005). CONCLUSIONS: Patients with nonproteinuric diabetic kidney disease had better-controlled blood pressure and fewer typical morphological changes and were at lower risk of CKD progression and all-cause mortality.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study. Diabetes Care. 2019. PMID: 30833372. doi:10.2337/dc18-1320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。